Announcement on Voluntary Disclosure of Clinical Trial Applications for 7MW4911 Injection Accepted by China NMPA and U.S. FDA

About this update from Mabwell (shanghai) Bioscience Co., Ltd. Class A

Announcement on Voluntary Disclosure of Clinical Trial Applications for 7MW4911 Injection Accepted by China NMPA and U.S. FDAThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Mabwell (shanghai) Bioscience Co., Ltd. Class A